This Phase III trial is evaluating the effectiveness of targeted therapy (tafasitamab), compared with a placebo, is when combined with other cancer drugs (lenalidomide and rituximab) in people with relapsed or refractory follicular lymphoma or marginal zone lymphoma.
This trial is treating patients with follicular lymphoma and marginal zone lymphoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You have had treatment, but your cancer has come back.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma
This is a randomised, double blind trial with an experimental and a placebo comparator arm. Participants in the Experimental arm will receive tafasitamab + rituximab + lenalidomide. Tafasitamab will be administered intravenously (IV) for 12 cycles. Rituximab will be administered via IV on cycles 1-5. Lenalidomide will be administered orally for 12 cycles. Participants in the Placebo Comparator arm will receive placebo + rituximab + lenalidomide. The Placebo will be administered via IV for 12 cycles. Rituximab will be administered via IV on cycles 1-5. Lenalidomide will be administered orally for 12 cycles.
Recruiting Hospitals Read More